AJR Am J Roentgenol

1. BURGIO MD
   Prognostic Value of LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024 in Hepatocellular Carcinoma Treated with Y-90 Radioembolization.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33219.
   

   >> Share

   
   
2. KELLER EJ
   If You Can Superselect a Hepatic Artery, You Can Learn Prompt Engineering.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33212.
   

   >> Share

   
   
3. HORII SC
   Determination of the Hepatic Attenuation Coefficient: Importance of a Scanning Protocol That Accounts for the Ultrasound Machine and Depth of the Hepatic ROI.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33148.
   

   >> Share

   
   
4. GABRIEL H
   The Urgent Need for Standardizing Ultrasound Quantification of Hepatic Steatosis.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33161.
   

   >> Share

   
   

   
   Am J Gastroenterol

5. HWANG SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, et al
   Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
   Am J Gastroenterol. 2025 May 16. doi: 10.14309/ajg.0000000000003546.
   

   >> Share

   
   

   
   Am J Pathol

6. XUE Y, Tian T, Ottallah M, Mannan M, et al
   Alcohol-Associated Hepatocarcinogenesis: Wnt/beta-Catenin in Action.
   Am J Pathol. 2025 May 9:S0002-9440(25)00156-7. doi: 10.1016/j.ajpath.2025.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

7. FAN M, Wu J, Wu Y, Zhang Y, et al
   SETDB1 decline promotes the resistance to sorafenib via DRP1 phosphorylation-mediated mitochondrial dysfunction in HepG2 cells.
   Biochem Biophys Res Commun. 2025;768:151934.
   

   >> Share

   
   

   
   BMC Cancer

8. HOSSEINKHAN N, Najafi L, Jahangiri S, Emami Z, et al
   Statin use and risk of HCC in patients with MASLD and T2DM: an umbrella review and meta-analysis.
   BMC Cancer. 2025;25:875.
   

   >> Share

   
   
9. SHU Z, Ye T, Wu W, Su M, et al
   Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study.
   BMC Cancer. 2025;25:867.
   

   >> Share

   
   
10. YANG H, Shen S, Yang Y, Zhou H, et al
    Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.
    BMC Cancer. 2025;25:855.
    

    >> Share

    
    
11. REIERSON MM, Acharjee A
    Unsupervised machine learning-based stratification and immune deconvolution of liver hepatocellular carcinoma.
    BMC Cancer. 2025;25:853.
    

    >> Share

    
    
12. PELOSO A, Pietrasz D, Daillier E, Cylly L, et al
    Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial.
    BMC Cancer. 2025;25:848.
    

    >> Share

    
    

    
    BMC Gastroenterol

13. XU S, Ji Q, Xu J
    Evaluating the diagnostic significance of the R2* value on 3.0T MRI for assessing the severity of warm hepatic ischemia-reperfusion injury.
    BMC Gastroenterol. 2025;25:361.
    

    >> Share

    
    
14. YE D, Wang J, Shi J, Ma Y, et al
    Prevalence of MAFLD in the U.S. based on NHANES 2009-2018: differences in demographic characteristics, physical indices and lifestyle conditions.
    BMC Gastroenterol. 2025;25:329.
    

    >> Share

    
    
15. LE XY, Feng JB, Yu XL, Li SL, et al
    A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.
    BMC Gastroenterol. 2025;25:360.
    

    >> Share

    
    
16. QIAO G, Feng L, Wang M, Wang C, et al
    Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to the healing of hepatogenic ulcer.
    BMC Gastroenterol. 2025;25:359.
    

    >> Share

    
    
17. XU Z, Xu B
    Nonlinear association between AST/ALT ratio and 28-day all-cause mortality following ICU admission in critically ill cirrhotic patients: a retrospective cohort study.
    BMC Gastroenterol. 2025;25:367.
    

    >> Share

    
    
18. LIU G, Mao Q, Tian X, Zhang C, et al
    Association of biological aging and the prevalence of nonalcoholic fatty liver disease: a population-based study.
    BMC Gastroenterol. 2025;25:368.
    

    >> Share

    
    
19. MATSUMOTO K, Doi S, Adachi T, Watanabe A, et al
    Surface area outcomes in EUS-guided liver biopsy: a comparative study of Franseen and Fork-tip needles.
    BMC Gastroenterol. 2025;25:370.
    

    >> Share

    
    
20. WU J, Yu W, Huang L, Hou S, et al
    The HbA1c/HDL-C ratio as a screening indicator of NAFLD in U.S. adults: a cross-sectional NHANES analysis (2017-2020).
    BMC Gastroenterol. 2025;25:369.
    

    >> Share

    
    
21. PENG HY, Lu CL, Zhao M, Huang XQ, et al
    Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders.
    BMC Gastroenterol. 2025;25:372.
    

    >> Share

    
    
22. WANG X, Chen H, Wang L, Sun W, et al
    Machine learning for predicting all-cause mortality of metabolic dysfunction-associated fatty liver disease: a longitudinal study based on NHANES.
    BMC Gastroenterol. 2025;25:376.
    

    >> Share

    
    
23. WANG C
    Role of liver transient elastography in detecting cirrhosis with esophageal and gastric varices and evaluating variceal severity.
    BMC Gastroenterol. 2025;25:379.
    

    >> Share

    
    

    
    Endoscopy

24. INOUE T, Kitano R, Kitada T, Futagami S, et al
    Endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting using a catheter-like delivery system: a novel technique completely omitting the fistula dilation step.
    Endoscopy. 2025;57.
    

    >> Share

    
    

    
    Eur Radiol

25. VERDAN S, Torri GB, Marcos VN, Moreira MHS, et al
    Ultrasound-derived fat fraction for diagnosing hepatic steatosis: a systematic review and meta-analysis.
    Eur Radiol. 2025 May 9. doi: 10.1007/s00330-025-11652.
    

    >> Share

    
    
26. ELBANNA KY, Khalili K, AlMoharb M, Goel A, et al
    Qualitative and quantitative assessment of gadoxetic acid MRI in distinguishing atypical focal nodular hyperplasia from hepatocellular adenoma subtypes.
    Eur Radiol. 2025 May 14. doi: 10.1007/s00330-025-11679.
    

    >> Share

    
    
27. TIE J, Yuan X, Liu Z, Gou X, et al
    Transjugular mesenteric-caval shunt for portal vein cavernous transformation with recurrent variceal bleeding: preliminary results.
    Eur Radiol. 2025;35:3256-3261.
    

    >> Share

    
    
28. KOBAYASHI T, Kozaka K, Matsubara T, Yokka A, et al
    Super delayed phase imaging in gadoxetic acid-enhanced MRI: investigating factors contributing to improved liver contrast.
    Eur Radiol. 2025;35:3195-3205.
    

    >> Share

    
    
29. LI J, Li Y, Chen YY, Wang XY, et al
    Predicting post-hepatectomy liver failure with T1 mapping-based whole-liver histogram analysis on gadoxetic acid-enhanced MRI: comparison with the indocyanine green clearance test and albumin-bilirubin scoring system.
    Eur Radiol. 2025;35:3587-3598.
    

    >> Share

    
    
30. JING HH, Hao D, Liu XJ, Cui MJ, et al
    Development and validation of a radiopathomics model for predicting liver metastases of colorectal cancer.
    Eur Radiol. 2025;35:3409-3417.
    

    >> Share

    
    
31. IMAJO K, Saigusa Y, Kobayashi T, Nagai K, et al
    Head-to-head comparison among FAST, MAST, and multiparametric MRI-based new score in diagnosing at-risk MASH.
    Eur Radiol. 2025;35:3599-3609.
    

    >> Share

    
    
32. EL HOMSI M, Bou Ayache J, Fernandes MC, Horvat N, et al
    Comparison of abbreviated and complete MRI protocols for treatment response assessment of colorectal liver metastases.
    Eur Radiol. 2025;35:3450-3459.
    

    >> Share

    
    
33. JENSEN CT, Wong VK, Likhari GS, Daoud TE, et al
    Dual-energy CT for differentiation of hypodense liver lesions in pancreatic adenocarcinoma.
    Eur Radiol. 2025;35:3538-3546.
    

    >> Share

    
    
34. JIANG H, Li B, Zheng T, Qin Y, et al
    MRI-based prediction of microvascular invasion/high tumor grade and adjuvant therapy benefit for solitary HCC
    Eur Radiol. 2025;35:3223-3237.
    

    >> Share

    
    

    
    Gastroenterology

35. SHUNG DL, Iacucci M
    Artificial Intelligence in Gastroenterology and Hepatology: Potential and Perils.
    Gastroenterology. 2025 May 13:S0016-5085(25)00710.
    

    >> Share

    
    

    
    Hepatology

36. JIN Y, Wang M, Xu A, Xu B, et al
    Letter to the Editor: Association between mean arterial pressure and terlipressin in the reversal of hepatorenal syndrome-acute kidney injury.
    Hepatology. 2025 May 15. doi: 10.1097/HEP.0000000000001404.
    

    >> Share

    
    
37. WANG Y, Yang L, Li M, Hao J, et al
    Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation.
    Hepatology. 2025 May 12. doi: 10.1097/HEP.0000000000001389.
    

    >> Share

    
    
38. WANG C, Dong D, Zhao N, Zhao S, et al
    Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001393.
    

    >> Share

    
    
39. YANG DL, Li YF, Li YJ, Qiu GG, et al
    Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001395.
    

    >> Share

    
    
40. YU TC, Zhao L, Sze KM, Tian L, et al
    GPD1L supports glycerol-3-phosphate and triacylglycerol synthesis and promotes tumor progression in hepatocellular carcinoma.
    Hepatology. 2025 May 9. doi: 10.1097/HEP.0000000000001394.
    

    >> Share

    
    

    
    J Comput Assist Tomogr

41. ZHU X, Zhu J, Sun C, Zhu F, et al
    Prediction of Local Tumor Progression After Thermal Ablation of Colorectal Cancer Liver Metastases Based on Magnetic Resonance Imaging Delta-Radiomics.
    J Comput Assist Tomogr. 2025;49:377-384.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

42. LIOU WL, Tan SY, Yamada H, Krishnamoorthy T, et al
    Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study.
    J Gastroenterol Hepatol. 2025 May 10. doi: 10.1111/jgh.16997.
    

    >> Share

    
    
43. QIN J, Zhu W, Zhou W
    Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?
    J Gastroenterol Hepatol. 2025 May 13. doi: 10.1111/jgh.16991.
    

    >> Share

    
    
44. CHANG YW, Kuo CN, Chang CL, Hsu JC, et al
    Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World Evidence From Regorafenib and Trifluridine/Tipiracil Use.
    J Gastroenterol Hepatol. 2025;40:1135-1142.
    

    >> Share

    
    
45. FUKAMIZO K, Hagiwara Y, Kimura T, Matsuyama Y, et al
    Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in Japanese Non-Obese Individuals.
    J Gastroenterol Hepatol. 2025;40:1255-1262.
    

    >> Share

    
    
46. DONG L, Zhang H, Kang Y, Wang F, et al
    NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated Liver Disease.
    J Gastroenterol Hepatol. 2025;40:1070-1078.
    

    >> Share

    
    

    
    J Hepatol

47. 
    EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease.
    J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
48. CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
    Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis.
    J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    

    
    Lancet

49. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    

    >> Share

    
    
50. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    

    >> Share

    
    

    
    N Engl J Med

51. NOUREDDIN M, Rinella ME, Chalasani NP, Neff GW, et al
    Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
    N Engl J Med. 2025 May 9. doi: 10.1056/NEJMoa2502242.
    

    >> Share

    
    

    
    Oncogene

52. DENG L, Tang J, Yang H, Cheng C, et al
    Retraction Note: MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
    Oncogene. 2025 May 12. doi: 10.1038/s41388-025-03433.
    

    >> Share

    
    

    
    PLoS One

53. TAKADA H, Osawa L, Komiyama Y, Muraoka M, et al
    Serum interferon-gamma-induced protein 10 levels can help predict sarcopenia development in patients with primary hepatocellular carcinoma: A retrospective cohort study.
    PLoS One. 2025;20:e0309852.
    

    >> Share

    
    
54. NGAMSANGIAM W, Techa-Ay S, Sa-Ngiamwibool P, Watcharadetwittaya S, et al
    Distinct chromosome abnormality patterns for differential diagnosis of hepatocellular carcinoma and cholangiocarcinoma.
    PLoS One. 2025;20:e0322408.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share